Compositions comprising isolated ido-BR1 are described for use in therapy or prophylaxis, including the treatment of inflammatory diseases (for example as anti-inflammatory drugs) and to reduce inflammation. Also described are methods for monitoring the quality of a Cucurbitaceae extract, to process
Compositions comprising isolated ido-BR1 are described for use in therapy or prophylaxis, including the treatment of inflammatory diseases (for example as anti-inflammatory drugs) and to reduce inflammation. Also described are methods for monitoring the quality of a Cucurbitaceae extract, to processes for producing a Cucurbitaceae extract as well as to Cucurbitaceae extracts obtainable by such processes.
대표청구항▼
1. A method for treating an inflammatory disease comprising administering an effective amount of a composition comprising (2R,3R,4R,5S)-3,4,5-trihydroxypiperidine-2-carboxylic acid, or a pharmaceutically acceptable salt thereof, and a pharmaceutically-acceptable excipient or carrier, to a subject in
1. A method for treating an inflammatory disease comprising administering an effective amount of a composition comprising (2R,3R,4R,5S)-3,4,5-trihydroxypiperidine-2-carboxylic acid, or a pharmaceutically acceptable salt thereof, and a pharmaceutically-acceptable excipient or carrier, to a subject in need thereof. 2. The method of claim 1, wherein the inflammatory disease is an autoimmune disease. 3. The method of claim 2, wherein the autoimmune disease is ulcerative colitis. 4. The method of claim 2, wherein the autoimmune disease is inflammatory bowel disease. 5. The method of claim 2, wherein the autoimmune disease is rheumatoid arthritis. 6. The method of claim 1, wherein the inflammatory disease is psoriatic arthritis. 7. The method of claim 1, wherein the inflammatory disease is enteropathic arthritis. 8. The method of claim 1, wherein the inflammatory disease is reactive arthritis. 9. The method of claim 1, wherein the inflammatory disease is arthritis associated with inflammatory bowel disease. 10. The method of claim 1, wherein the (2R,3R,4R,5S)-3,4,5-trihydroxypiperidine-2-carboxylic acid, or pharmaceutically acceptable salt thereof, is present in the composition at a level of about 1% w/w to about 50% w/w (on a dry weight basis). 11. The method of claim 1, wherein the (2R,3R,4R,5S)-3,4,5-trihydroxypiperidine-2-carboxylic acid, or pharmaceutically acceptable salt thereof, is present in the composition at a level of about 50% w/w to about 99% w/w (on a dry weight basis). 12. The method of claim 1, wherein the (2R,3R,4R,5S)-3,4,5-trihydroxypiperidine-2-carboxylic acid, or pharmaceutically acceptable salt thereof, is present in the composition at a level of up to 1% w/w (on a dry weight basis). 13. The method of claim 1, wherein the (2R,3R,4R,5S)-3,4,5-trihydroxypiperidine-2-carboxylic acid, or pharmaceutically acceptable salt thereof, is present in the composition at a level of up to 5% w/w (on a dry weight basis). 14. The method of claim 1, wherein the (2R,3R,4R,5S)-3,4,5-trihydroxypiperidine-2-carboxylic acid, or pharmaceutically acceptable salt thereof, is present in the composition at a purity level of at least 90% w/w. 15. The method of claim 1, wherein the (2R,3R,4R,5S)-3,4,5-trihydroxypiperidine-2-carboxylic acid, or pharmaceutically acceptable salt thereof, is administered topically. 16. The method of claim 1, wherein the (2R,3R,4R,5S)-3,4,5-trihydroxypiperidine-2-carboxylic acid, or pharmaceutically acceptable salt thereof, is orally administered. 17. The method of claim 1, wherein the (2R,3R,4R,5S)-3,4,5-trihydroxypiperidine-2-carboxylic acid, or pharmaceutically acceptable salt thereof, is parenterally administered. 18. The method of claim 1, wherein the (2R,3R,4R,5S)-3,4,5-trihydroxypiperidine-2-carboxylic acid, or pharmaceutically acceptable salt thereof, is administered by buccal or sublingual application. 19. The method of claim 1, further comprising administering an anti-inflammatory agent. 20. The method of claim 19, wherein the effective amount is about 0.1 mg/kg to about 50 mg/kg of (2R,3R,4R,5S)-3,4,5-trihydroxypiperidine-2-carboxylic acid, or pharmaceutically acceptable salt thereof, administered daily.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.